Drugs / KD033
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04242147 | Mar → Dec 2023 | cancer | Kadmon, a Sanofi Company | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KD033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04242147 ↗ |
| Known as | SAR445710 | “KD033 (SAR445710)” NCT04242147 ↗ |